ChAdOx1.5Ag/MVA.5Ag
ChAdOx1.5Ag is a recombinant, replication deficient chimpanzee adenovirus, expressing the four antigens of the mycobacterium Esx-5a system (PPE15, PE8, EsxI, EsxJ), along with Ag85A. In mice, ChAdOx1.5Ag improved the efficacy of BCG in the lung and spleen, and a further boost with MVA.5Ag further improved efficacy in the spleen. ChAdOx1.5Ag/MVA.5Ag was also promising in non-human…
Read MoreSpore-FP1
Spore-FP1 is a subunit vaccine candidate consisting of inactivated Bacillus subtilis spores coated with the FP1 fusion protein and formulated with Poly(I:C) adjuvant. FP1 fusion protein comprises Ag85B, Acr/HspX and the N-terminal domain of HBHA antigen. It is intended as a mucosal boost vaccine in BCG-immunised hosts.
Read MoreMtbDsigH
The parental candidate is an isogenic mutant in Mtb CDC1551 gene Rv3223c (sigH). We have now generated multiple Mtb double and triple knock-out (DKO, TKO) strains including: DsigHDsecA2DsodA, DsigHDfbpADsapM, DsigHDleuCDpanCD, DsigHDmetA, DsigHDmce4EDmce4F, DsigHDfadD29, DsigHDhadC, DsigHDRv3683, DsigHDmce1A, DsigHDcobM.
Read MoreSpray Dried ID93+GLA-SE
AAHI’s tuberculosis vaccine candidate includes a recombinant fusion subunit protein antigen, ID93, formulated with GLA-SE, a squalene emulsion containing the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA). The vaccine candidate was developed on AAHI’s formulation (adjuvant and delivery vehicle) vaccine platform.
Read MoreChAdOx1.85A+MVA85A*
ChAdOx1.85A is a simian adenoviral vector expressing Antigen 85A. MVA85A is a modified vaccinia virus Ankara expressing Antigen 85A. The target route of administration for ChAdOx1.85A is aerosol, and intramuscular for MVA85A.
Read More